CN107001487A - 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于改善性功能的组合物 - Google Patents
含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于改善性功能的组合物 Download PDFInfo
- Publication number
- CN107001487A CN107001487A CN201580059702.XA CN201580059702A CN107001487A CN 107001487 A CN107001487 A CN 107001487A CN 201580059702 A CN201580059702 A CN 201580059702A CN 107001487 A CN107001487 A CN 107001487A
- Authority
- CN
- China
- Prior art keywords
- pore fungi
- culture liquid
- exocellular polysaccharide
- mycelium culture
- wax pore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000233866 Fungi Species 0.000 title claims abstract description 71
- 239000011148 porous material Substances 0.000 title claims abstract description 70
- 150000004676 glycans Chemical class 0.000 title claims abstract description 61
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 61
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000036299 sexual function Effects 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 70
- 239000000843 powder Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 230000006870 function Effects 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 238000009630 liquid culture Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 235000012054 meals Nutrition 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229910001868 water Inorganic materials 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 240000006394 Sorghum bicolor Species 0.000 claims description 4
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 235000014786 phosphorus Nutrition 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract description 7
- 201000001881 impotence Diseases 0.000 abstract description 7
- 241001466515 Emmia lacerata Species 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000001965 potato dextrose agar Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000438 udenafil Drugs 0.000 description 3
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical group C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- MZNDIOURMFYZLE-UHFFFAOYSA-N butan-1-ol Chemical compound CCCCO.CCCCO MZNDIOURMFYZLE-UHFFFAOYSA-N 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- BAPROVDXKNPHAM-UHFFFAOYSA-N n-(2-aminoethyl)-3-(3,5-ditert-butyl-4-hydroxyphenyl)propanamide Chemical compound CC(C)(C)C1=CC(CCC(=O)NCCN)=CC(C(C)(C)C)=C1O BAPROVDXKNPHAM-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- -1 phosphoric acid hydrogen Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Materials Engineering (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Sustainable Development (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pediatric Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于改善性功能的组合物,所述用于改善性功能的组合物含有如下有效成分:由撕裂蜡孔菌(Ceriporia lacerata)生成的胞外多糖、包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物,所述组合物能够作为用于预防或治疗勃起功能障碍或者糖尿病勃起功能障碍的性功能改善剂,或者作为具有改善性功能效能的健康功能食品得到使用。
Description
技术领域
本发明涉及一种用于改善性功能的组合物,所述用于改善性功能的组合物含有如下有效成分:由撕裂蜡孔菌(Ceriporia lacerata)生成的胞外多糖、或包含胞外多糖的撕裂蜡孔菌的菌丝体培养液、菌丝体培养液的干燥粉末或提取物。
背景技术
男性的性功能由性欲、阴茎勃起、射精及性高潮构成。阴茎勃起是由于如下现象而被诱发:通过勃起神经的刺激使得海绵体平滑肌弛缓,从而小孔得到膨胀,由于小动脉扩张引起的血流增加而使得阴茎内压增加,据此,在较硬的白膜和小孔之间存在的白膜下静脉由于小孔的膨胀而被挤压,从而阻止静脉血的流出,因此使得阴茎内压更加增加。
根据统计,成人男性中约20~60%诉苦性功能障碍,而且呈现随着年龄的增加发病率也增加的趋势。就在10余年前所述性功能障碍被认为大部分是因为心理性问题,但是随着现代医学的发达,被揭示性功能障碍患者的约50%以上是由于血管系统、神经系统以及内分泌系统疾病、糖尿病、高血压、药物服用等器质性原因引起的。
最近,作为口服用勃起功能障碍治疗剂得到了开发并在全世界正在使用的西地那非(sildenafil,商品名:伟哥(Viagra))被广为人知,其使得特异性分布于阴茎海绵体的PDE-5(磷酸二酯酶-5(phosphodiesterase-5))的阻碍引起的cGMP的浓度增加,因此使得阴茎海绵体内血流增大,从而诱导勃起,并具有勃起功能障碍的治疗效果。此外,通常作为勃起功能障碍治疗剂广为人知的PDE-5抑制剂,其作为环鸟苷酸3',5'-单磷酸盐(cyclicguanosine 3',5'-monophosphate)-特异性磷酸二酯酶五型(cGMP-特异性PDE-5)酶的选择性抑制剂,有乌地那非(Udenafil,C25H36N6O4S)、西地那非(Sildenafil,C22H30N6O4S)、伐地那非(Vardenafil,C23H33N6O4S)以及他达拉非(Tadalafil,C22H19N3O4)等,所述药物分别公开于韩国专利第0353014号(乌地那非)、韩国专利第0262926号(西地那非)、韩国专利第0430355号(伐地那非)、韩国专利第0357411号(他达拉非)。但是,现有的药物被报告有头痛、热潮红、消化不良及心脏麻痹等很多副作用,从而要求可代替或者补充它们的新的药剂的必要性。
因此,实情为,要求开发一种没有由现有治疗方法带来的副作用且不是化学合成的产品、以天然物为主要原料的男性性功能改善剂。天然物的临床效能很久以前就得到了证实,通常比化学物质副作用少,因此是用于开发改善性功能的组合物的合适的候补物质。
众所周知,撕裂蜡孔菌作为白腐菌的一种,为了在生态界利用纤维素(cellulose)、半纤维素(hemicellulose)、其他多糖类及甘油(glycerol)等碳源,执行被称为木质素(lignin)分解的共代谢(cometabolism)。但是实情为,撕裂蜡孔菌自2002年首次在学界得到报告后,其的产业化研究尚不完备。
对此,本发明人发现由撕裂蜡孔菌生成的胞外多糖或包含胞外多糖的撕裂蜡孔菌的菌丝体培养液、菌丝体培养液的干燥粉末或提取物具有改善性功能的效果,并完成本发明,本发明涉及将其作为有效成分含有的用于改善性功能的组合物。
发明内容
本发明的目的在于,提供一种含有由撕裂蜡孔菌生成的药理活性成分的用于改善性功能的组合物。
本发明的又另一个目的在于,提供一种含有由撕裂蜡孔菌生成的药理活性成分的用于改善性功能的健康功能食品。
为了实现所述目的,本发明提供一种含有如下成分作为有效成分的用于改善性功能的组合物:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
为了实现所述目的,本发明提供一种含有如下成分作为有效成分的具有改善性功能效能的健康功能食品:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
为了实现所述目的,本发明提供一种改善性功能方法,所述方法包括将如下成分用药于需要改善性功能的对象:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末或所述菌丝体培养液的提取物。
为了实现所述目的,本发明提供一种用于制造改善性功能的药剂的由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或所述菌丝体培养液的提取物的用途。
根据本发明的含有由撕裂蜡孔菌生成的胞外多糖或包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末或提取物作为有效成分的组合物因为表现出对PDE-5活性的抑制效果,所以能够有效地用作改善性功能的用途。
附图说明
图1是表示由撕裂蜡孔菌(Ceriporia lacerata)生成的胞外多糖的对PDE-5活性的抑制效果的图表。
具体实施方式
以下,对本发明进行详细说明。
本发明提供一种用于改善性功能的组合物,所述用于改善性功能的组合物含有如下有效成分:由撕裂蜡孔菌(Ceriporia lacerata)生成的胞外多糖、或包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末或提取物。
就根据本发明的组合物而言,所述胞外多糖可以包括约40~60重量%的糖和约30~40重量%的蛋白质、约40~50重量%的糖和约32~38重量%的蛋白质、或约43~47重量%的糖和约33~36重量%的蛋白质,优选地,可以包括约45重量%的糖和约34重量%的蛋白质。
所述糖可含有甘露糖(mannose)、半乳糖(galactose)及葡萄糖(glucose)。
所述胞外多糖可具有约100~150kDa、约110~140kDa或约115~125kDa的分子量,优选地可具有约120kDa的分子量。
作为一个优选的具体例子,所述胞外多糖可通过包括如下步骤的制造方法制造:
(a)对撕裂蜡孔菌的菌丝体进行液体培养,从而制造撕裂蜡孔菌的菌丝体培养液;
(b)使得撕裂蜡孔菌的菌丝体培养液干燥从而进行粉末化;以及
(c)用溶剂对撕裂蜡孔菌的菌丝体培养液粉末进行提取后,对其进行过滤并减压浓缩。
在所述(a)步骤中的用于对撕裂蜡孔菌菌丝体进行液体培养的培养基包括糖、葡萄糖、淀粉、高粱粉、大麦粉、大豆粉、硫酸镁(MgSO4)、磷酸二氢钾(KH2PO4)、磷酸氢二钾(K2HPO4)及水,氢离子浓度(pH)可以为4.5~6.0。
作为一个优选的具体例子,所述培养基可包括糖0.2~3重量%、葡萄糖0.2~3重量%、淀粉0.2~4重量%、高粱粉0.1~0.5重量%、大麦粉0.1~0.5重量%、大豆粉0.2~3重量%、硫酸镁(MgSO4)0.05~0.1重量%、磷酸二氢钾(KH2PO4)0.05~0.25重量%、磷酸氢二钾(K2HPO4)0.05~0.25重量%,剩余为水。
在所述(a)步骤中的液体培养可以在蓝色LED光源下执行,并且可以将二氧化碳的浓度保持在1,000~2,000ppm的状态下执行。
此时,就液体培养而言,例如,在20~25℃下,氢离子浓度(pH)为4.5~6.0,光源为蓝色LED,光照度保持0.5LUX,并且空气以0.5~1.5kgf/cm2注入,二氧化碳的浓度保持为1,000~2,000ppm的同时可进行8~13天,在22℃、pH5.0、1.0kgf/cm2、1,500ppm条件下进行10天,此时胞外多糖的含量较高,因此是优选的。
作为所述(a)步骤中的亲株可使用经过如下培养过程的物质:将以马铃薯葡萄糖琼脂(Potato dextrose agar,PDA)培养基状态在4℃下保管中的1个优良菌株,在锥形瓶上使用马铃薯葡萄糖肉汤(potato dextrose broth,PDB)培养基,并在振荡培养器中,保持25℃的恒温,并经过7~9天培养。此时,作为接种体要投入的菌丝体的量以将要培养的溶液的量为基准,优选为0.5%(w/v)程度。菌丝体量(%/100ml)多,并非胞外多糖的含量也一起升高,因此优选地,培养基组成使用使得胞外多糖的含量形成得最高的选择性培养条件,而不是对菌丝体的生长最好的营养比例及环境条件。
所述培养液能够分离精制为菌丝体和水溶液。为了所述分离精制,可通过多片压滤机(Multi-Sheet Filter Press)和震动离心膜分离机(PALLSEP)对通过离心分离机去除菌丝体的溶液进行反复精制后,进行1分钟紫外线(UV)照射。此外,溶液需要在去除氧后进行密封保管,这是因为,溶液中存在菌丝的情况下,氧使得菌丝生长,并致使有效成分的含量发生变化。
在所述(b)步骤中,使得在所述(a)步骤所制造的菌丝体培养液真空干燥或冻结干燥,从而能够粉末化。优选地,所述干燥为了防止消除有效物质,在40℃以下的温度,优选地,在30℃以下的温度下执行48~96小时。并且优选地,就在(b)步骤中的干燥而言,相比真空干燥机使用真空冻结干燥机使得有效物质含量变化最小化,所述真空干燥机将蒸发温度设置为相对较高。
在所述(c)步骤中,用溶剂对在(b)步骤中所得到的菌丝体培养液干燥粉末进行提取后,对根据本发明的组合物的有效成分胞外多糖进行分离、制造。具体而言,干燥粉末5g中添加蒸馏水100mL,从而充分悬浊后,进行离心分离(8,000rpm,20min),从而能够向其的上清液中添加相当于其的量的2~3倍的提取溶剂,并放置于冰箱(4℃),从而静放12小时。在所述的静放物中仅对上清液重新进行离心分离(8,000rpm,20min)后,回收沉淀物,从而能够制造粗制(crude)的胞外多糖。优选地,在30℃以下对所述粗制的胞外多糖进行真空冻结干燥。
所述提取溶剂可以是选自由如下物质组成的群中的溶剂或它们的混合溶剂:水、乙醇(ethanol)、甲醇(methanol)、丙酮(acetone)、丁醇(butanol)及乙酸乙酯(EthylAcetate),并且优选地,可以是水或50%(w/w)~80%(w/w)的乙醇水溶液。
在根据本发明的含有由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末或提取物作为有效成分的用于改善性功能的组合物中还可包括通常使用的适当的担体、赋形剂及稀释剂。
相对于组合物总重量,包含0.1至80重量%的所述胞外多糖,优选地可包含0.1至50重量%,并且撕裂蜡孔菌的菌丝体培养液、菌丝体培养液的干燥粉末或提取物能够以相当于所述胞外多糖的含量的量适当地被包含。但是,最优选的胞外多糖或包含胞外多糖的培养液、培养液的干燥粉末或提取物的有效含量能够根据组合物的使用方法及目的适当地调节。
可根据通常的方法分别对根据本发明的组合物进行剂型化并使用。作为适合的剂型有锭剂、丸剂、散剂、颗粒剂、糖衣片剂、硬质或软质的胶囊剂、溶液剂、悬浊剂或乳化液剂、注射剂、坐剂等,但是并非限定于此。
根据本发明的组合物能够利用药学非活性有机或无机担体来制造适当的剂型。换句话说,剂型为锭剂、涂覆的锭剂、糖衣片剂及硬质胶囊的情况,可以使用乳糖(lactose)、蔗糖(sucrose)、淀粉或其衍生物、滑石(talc)、碳酸钙(Calcium Carbonate)、明胶(gelatin)、硬脂酸(stearic acid)或其的盐。此外,剂型为软质胶囊的情况,可以使用植物性油、蜡(wax)、脂肪、半固体及液体的多元醇(polyol)。此外,剂型为溶液或糖浆(syrup)形态的情况,可以使用水、多元醇、甘油(glycerol)及植物性油等。
根据本发明的组合物除了所述担体以外,还可包括保存剂、稳定剂、湿润剂、乳化剂、溶解剂、甜味剂、着色剂、渗透压调节剂、防氧化剂等。
根据本发明的组合物的用药方法能够根据剂型而易于选择,并且能够进行口服或非口服用药。用药量虽然根据患者的年龄、性别、体重、病情、用药途径而可以不同,但是通常以有效成分胞外多糖为基准,5至500mg/kg的量,优选地,能够将100至250mg/kg的量按照每天一次至三次进行用药。但是,所述用药量无论从任何方面来讲都不对本发明的范围构成限定。
根据本发明的组合物不仅提供优秀的改善性功能效果,而且几乎不存在药物毒性及副作用,从而以改善性功能为目的而长期用药也能够放心。由此,本发明的组合物能够用于需要改善性功能的疾病,例如,勃起功能障碍、糖尿病勃起功能障碍等的预防及治疗。
此外,本发明提供用于改善性功能的健康功能食品,所述健康功能食品含有如下有效成分:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
根据本发明的健康功能食品可以是粉末、颗粒、锭剂、胶囊或饮料的形态,可以是糖果、巧克力、饮料、口香糖、茶、维他命复合剂、健康辅助食品等。
此时,所述食品中的根据本发明的胞外多糖或包含胞外多糖的菌丝体培养液、菌丝体培养液的干燥粉末或提取物通常为整体食品重量的0.01至50重量%,优选地以0.1至20重量%的形式被包含,健康饮料组合物的情况,能够以100ml为基准,以0.02至10g的形式,优选地以0.3至1g的比例被包含。
所述食品中,与本发明的由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物一起,还可包括食品学能够允许使用的食品辅助添加剂。
本发明提供改善性功能方法,所述方法包括将如下成分用药于需要改善性功能的对象:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
所述需要改善性功能的对象可以是哺乳动物,更为具体地可以是人类。
此外,本发明提供用于制造改善性功能药剂的由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液、所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物的用途。
所述由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物如前所述。
此外,所述改善性功能方法能够用于需要改善性功能的疾病,例如,勃起功能障碍、糖尿病勃起功能障碍等的预防及治疗。
以下,通过以下实施例对本发明进行更加详细的说明。但是,以下实施例只是用于对本发明进行示例,本发明的范围并非限定于此。
【实施例】
制造例1.撕裂蜡孔菌培养液、其的干燥粉末、提取物及胞外多糖(exopolysaccharide;以下称“EPS”)的制造
1.1撕裂蜡孔菌培养液的制造
使得从在庆尚北道尚州市采集的柞树活组织中分离的撕裂蜡孔菌,通过传代培养而培养毛霉菌,将其在-80℃进行冷冻保管,并将保管中的菌株在PDA(Potato dextroseagar)培养基(87塑料培养皿;培养基(Difco),贝克顿迪金森公司(Becton Dickinson andCompany))中传代2~3次后,将菌株(以下称为“PDA培养菌株”)在4℃冰箱中保管后进行使用。并且在锥形瓶上形成PDB(Potato dextrose broth)培养基(Difco,Becton Dickinsonand Bompany)600ml后,在此放入一个PDA培养菌株,并在25℃下进行八天的震荡培养,从而获得了PDB培养菌株。
之后,将液体培养培养基在800L发酵槽中以1.5kgf/cm2形式注入121℃的空气并杀菌20分钟后,在冷却至23℃的状态下,作为起子(starter)接种PDB培养菌株600ml,并以0.5~1.5kgf/cm2进行通气的同时,光源为蓝色LED,照度保持在0.5LUX,二氧化碳的浓度为2,000ppm,并且使得撕裂蜡孔菌菌丝体在23℃的恒温下进行10天的液体培养,从而制造撕裂蜡孔菌菌丝体培养液,所述液体培养培养基包括:糖1.5重量%、葡萄糖0.5重量%、土豆淀粉0.5重量%、高粱粉0.25重量%、大麦粉0.25重量%、大豆粉0.75重量%、硫酸镁(MgSO4)0.05重量%、磷酸二氢钾(KH2PO4)0.05重量%、磷酸氢二钾(K2HPO4)0.05重量%,剩余为水。
1.2撕裂蜡孔菌培养液干燥粉末的制造
通过真空冻结干燥机使得在制造例1.1中所制造的撕裂蜡孔菌菌丝体培养液在25℃下进行72小时的冻结干燥,从而使其粉末化,因此制造撕裂蜡孔菌菌丝体培养液的干燥粉末。
1.3撕裂蜡孔菌培养液提取物的制造
向在制造例1.2中所制造的撕裂蜡孔菌菌丝体培养液的干燥粉末5g中添加蒸馏水100ml,进行充分悬浊后,以8,000rpm进行20分钟离心分离后,向此上清液中加入相当于其量的2~3倍的乙醇,并在4℃下静放12小时。之后从静放物中提取上清液,从而制造撕裂蜡孔菌菌丝体培养液的提取物。
1.4从撕裂蜡孔菌培养液的EPS的制造
对在制造例1.3中所制造的撕裂蜡孔菌菌丝体培养液的提取物重新以8,000rpm进行20分钟离心分离后,回收沉淀物,从而获得粗制(crude)的EPS。使得所述粗制EPS在冻结干燥机中在25℃下真空冻结干燥72小时,从而获得由撕裂蜡孔菌生成的EPS。
实施例1.EPS的特性评价
1.1利用凝胶渗透色谱法(Gel Permeation Chromatography,GPC)进行的EPS的分
子量测定
使得所述制造例1中所制造的EPS在0.1M Na2SO4/0.05M NaN3(通过冰醋酸(glacial acetic acid)将PH调整为4)溶液中以成为1%(w/v)的形式溶解后,以4,000rpm进行0.5小时的离心分离,之后通过0.45μm针筒式过滤器(syringe filter)仅过滤上清液,从而通过GPC进行分析。
具体地,就GPC分析条件而言,通过检测器利用折射指数,就GPC柱层(column)而言,利用OHpak SB 805HQ(Shodex,Japan),就流动相而言,使用了0.1M Na2SO4/0.05M NaN3(通过冰醋酸将PH调整为4),流动相的流速以流速1.0mL/分钟的形式流入。标准曲线利用具有各自不同的分子量(130kDa、400kDa、770kDa或1200kDa)的葡聚糖(dextran)(AmericanPolymer Corporation,USA)来制作,并且利用折射指数(refractivity index,RI)测定器Knauer K-2310(Germany)来测定EPS的分子量。如果对测定条件进行整理,则如下表1。
【表1】
分子量的测定 | |
HPLC系统 | Knauer K-501系统 |
柱层 | OHpak SB 805 HQ(Shodex,Japan) |
流动相 | 0.1M Na2SO4/0.05M NaN3/pH 4 |
流速 | 1.0mL/min |
测定器 | RI(Knauer K-2310) |
结果,本发明的EPS的分子量表现为约120KDa。
1.2 EPS的糖及蛋白质含量测定
对在制造例1中所制造的EPS进行二次精制,并且用蛋白水解酶进行处理,从而测定糖及蛋白质含量。
具体而言,将一次精制的EPS(在制造例1中所制造的EPS)溶入蒸馏水后,以8,000rpm进行20分钟的离心分离,从而分离上清液后,向所分离的上清液添加相当于其量的2~3倍的乙醇,并放入4℃下的冰箱,从而静放12小时。之后,在静放物中再次仅对上清液以8,000rpm进行20分钟的离心分离后,对沉淀物进行回收,从而获得2次精制的EPS。将所述二次精制的EPS向蒸馏水溶解后,用作为蛋白水解酶的碱性蛋白酶(alcalase)以0.5%(w/v)的浓度在50℃下处理30分钟。
之后,糖含量通过酚-硫酸法(phenol-sulfuric acid method)进行测定。具体地,向按照不同浓度稀释的标本1mL中添加80%(v/v)酚25μL后,添加硫酸2.5mL,从而在室温下进行冷却,并在465nm下测定吸光度从而对糖含量进行计算。
此外,蛋白质含量通过BCA方法(参考Smith PK等,Analytical Biochemistry,150(1):76-85(1985))得到测定,并作为标准物质使用牛血清白蛋白(albumin)。
如上所述,测定的糖含量及蛋白质含量显示在如下表2,糖含量表现为45~51重量%,蛋白质含量表现为33~34重量%。
【表2】
*酶处理:碱性蛋白酶(Alcalase)0.5%,50℃,30分钟
各数值为平均±SE(n≥3)
此外,EPS的糖构成分析结果,EPS表现为主要含有甘露糖(mannose)、半乳糖(galactose)及葡萄糖(glucose)。
实施例2.EPS的改善性功能效果验证
为了调查从撕裂蜡孔菌菌丝体培养液所分离的EPS的性功能改善效果,以1ug/mL、3ug/mL、10ug/mL、30ug/mL及100ug/mL的浓度在PDE-5A分析试剂盒(获得处:BPS生物科学)对所述制造例1中所制造的EPS进行处理,从而参照记载于文献(Francis S.H.等,Prog.Nucleic Acid Res.&Molecular bio.,vol.65,pp.1-52,2001)的方法对PDE-5酶的抑制力进行测定。
将各个实验组的PDE-5活性表示于表3及图1中。
【表3】
如表3所示,能够确认的是,根据本发明的EPS的浓度随着从1ug/mL向30ug/mL增加,PDE-5活性逐渐减少。其表示根据本发明的EPS以浓度依赖性的形式阻碍PDE-5活性,此外,酶的活性减少50%的值的IC50值为29.5±1.236ug/mL。由此,所述结果显示根据本发明的EPS即使使用少量也具有改善性功能的效果。
Claims (13)
1.一种用于改善性功能的组合物,其含有如下有效成分:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
2.根据权利要求1所述的组合物,其特征在于,
所述胞外多糖包括40~60重量%的糖和30~40重量%的蛋白质,具有100~150kDa的分子量。
3.根据权利要求2所述的组合物,其特征在于,
所述胞外多糖包括43~47重量%的糖和33~36重量%的蛋白质,具有115~125kDa的分子量。
4.根据权利要求2所述的组合物,其特征在于,
所述糖含有甘露糖、半乳糖及葡萄糖。
5.根据权利要求1所述的组合物,其特征在于,
所述胞外多糖通过包括如下步骤的制造方法制造:
(a)对撕裂蜡孔菌的菌丝体进行液体培养,从而制造撕裂蜡孔菌的菌丝体培养液;
(b)使得撕裂蜡孔菌的菌丝体培养液干燥从而进行粉末化;以及
(c)用溶剂对撕裂蜡孔菌的菌丝体培养液粉末进行提取后,对其进行过滤并减压浓缩。
6.根据权利要求5所述的组合物,其特征在于,
用于所述液体培养的培养基包括糖、葡萄糖、淀粉、高粱粉、大麦粉、大豆粉、硫酸镁、磷酸二氢钾、磷酸氢二钾及水,氢离子浓度为pH 4.5~6.0。
7.根据权利要求5所述的组合物,其特征在于,
所述液体培养在蓝色LED光源下执行,并且将二氧化碳的浓度保持在1,000~2,000ppm的状态下执行。
8.根据权利要求1所述的组合物,其特征在于,
相对于组合物总重量,包含0.1至80重量%的所述胞外多糖。
9.一种用于改善性功能的健康功能食品,其含有如下有效成分:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
10.根据权利要求9所述的健康功能食品,其特征在于,
所述食品是粉末、颗粒、锭剂、胶囊或饮料的形态。
11.根据权利要求9所述的健康功能食品,其特征在于,
所述食品是糖果、巧克力、饮料、口香糖、茶、维他命复合剂、健康辅助食品等。
12.一种改善性功能方法,其包括将如下成分用药于需要改善性功能的对象:由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物。
13.一种用于制造改善性功能药剂的由撕裂蜡孔菌生成的胞外多糖;包含所述胞外多糖的撕裂蜡孔菌的菌丝体培养液;所述菌丝体培养液的干燥粉末;或者所述菌丝体培养液的提取物的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0151578 | 2014-11-03 | ||
KR1020140151578A KR101645652B1 (ko) | 2014-11-03 | 2014-11-03 | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물 |
PCT/KR2015/011722 WO2016072713A1 (ko) | 2014-11-03 | 2015-11-03 | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107001487A true CN107001487A (zh) | 2017-08-01 |
CN107001487B CN107001487B (zh) | 2020-04-03 |
Family
ID=55909373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580059702.XA Active CN107001487B (zh) | 2014-11-03 | 2015-11-03 | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于改善性功能的组合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9950022B2 (zh) |
KR (1) | KR101645652B1 (zh) |
CN (1) | CN107001487B (zh) |
WO (1) | WO2016072713A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100942794B1 (ko) * | 2009-11-03 | 2010-02-18 | 한남대학교 산학협력단 | 성기능 개선 효과를 나타내는 아르기닌 유도체 및 이의 염, 이를 포함하는 성기능 개선용 조성물 그리고 이의 제조방법 |
KR101031605B1 (ko) * | 2010-11-11 | 2011-04-27 | 김병천 | 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물 |
KR20110090217A (ko) * | 2010-02-03 | 2011-08-10 | 이상권 | 성기능 개선효과를 갖는 무수유산균발효 건강기능식품 조성물 및 그의 제조방법 |
US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
WO2014112665A1 (ko) * | 2013-01-18 | 2014-07-24 | (주)월드바이오텍 | 스테로이드 유도 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
WO2014112666A1 (ko) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | 세리포리아 라세라타 배양액 추출물의 제조방법 및 이로부터 제조된 세리포리아 라세라타 배양액 추출물을 유효성분으로 함유하는 당뇨성 질환 및 당뇨 합병증의 예방 또는 치료용 약학적 조성물 |
CN106998777A (zh) * | 2014-11-03 | 2017-08-01 | 福健生物制药有限公司 | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于镇定神经的组合物 |
CN108463123A (zh) * | 2014-11-03 | 2018-08-28 | 福健生物制药有限公司 | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于降血压的组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19881732D2 (de) | 1997-11-12 | 2000-08-24 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
KR20100077781A (ko) * | 2008-12-29 | 2010-07-08 | 정인학 | 발기부전에 효과적인 기능성 분말의 제조 방법, 이에 의한 기능성 분말을 포함하는 기능성 보조식품 |
KR101444614B1 (ko) | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | 세리포리아 락세라타 및 젖산균의 혼합배양을 통한 gaba가 증진된 발효물 제조방법 |
-
2014
- 2014-11-03 KR KR1020140151578A patent/KR101645652B1/ko active IP Right Grant
-
2015
- 2015-11-03 WO PCT/KR2015/011722 patent/WO2016072713A1/ko active Application Filing
- 2015-11-03 CN CN201580059702.XA patent/CN107001487B/zh active Active
- 2015-11-03 US US15/523,526 patent/US9950022B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100942794B1 (ko) * | 2009-11-03 | 2010-02-18 | 한남대학교 산학협력단 | 성기능 개선 효과를 나타내는 아르기닌 유도체 및 이의 염, 이를 포함하는 성기능 개선용 조성물 그리고 이의 제조방법 |
KR20110090217A (ko) * | 2010-02-03 | 2011-08-10 | 이상권 | 성기능 개선효과를 갖는 무수유산균발효 건강기능식품 조성물 및 그의 제조방법 |
KR101031605B1 (ko) * | 2010-11-11 | 2011-04-27 | 김병천 | 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물 |
US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
WO2014112665A1 (ko) * | 2013-01-18 | 2014-07-24 | (주)월드바이오텍 | 스테로이드 유도 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
WO2014112666A1 (ko) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | 세리포리아 라세라타 배양액 추출물의 제조방법 및 이로부터 제조된 세리포리아 라세라타 배양액 추출물을 유효성분으로 함유하는 당뇨성 질환 및 당뇨 합병증의 예방 또는 치료용 약학적 조성물 |
CN106998777A (zh) * | 2014-11-03 | 2017-08-01 | 福健生物制药有限公司 | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于镇定神经的组合物 |
CN108463123A (zh) * | 2014-11-03 | 2018-08-28 | 福健生物制药有限公司 | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于降血压的组合物 |
Non-Patent Citations (8)
Title |
---|
JAEJUNG LEE ET AL.: ""The antioxidant properties of solid-culture extracts of basidiomycetous fungi"", 《THE JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY》 * |
JI-EUN KIM ET AL.: ""Hyperglycemic Effect of Submerged Culture Extract of Ceriporia lacerata in Streptozotocin-induced Diabetic Rats"", 《FOOD SCI. BIOTECHNOL.》 * |
余多慰等: "《分子生物学(第1版)》", 31 July 2007, 南京师范大学出版社 * |
史军花: ""猴头菌发酵菌丝胞内多糖的分离纯化与结构研究"", 《中国优秀硕士学位论文全文数据库 基础科学辑》 * |
周磊: ""灵芝多糖的分离纯化和生物活性的研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
孔乐生等: ""赤灵芝GL-2发酵液中多糖组分及活性研究"", 《工业微生物》 * |
张晓昱等: ""白腐菌胞外羟自由基清除物质的产生"", 《华中科技大学学报》 * |
蒋红等: ""大叶南五味子多糖的分级与纯化"", 《中国农学通报》 * |
Also Published As
Publication number | Publication date |
---|---|
KR101645652B1 (ko) | 2016-08-08 |
CN107001487B (zh) | 2020-04-03 |
KR20160051468A (ko) | 2016-05-11 |
US20170312325A1 (en) | 2017-11-02 |
WO2016072713A1 (ko) | 2016-05-12 |
US9950022B2 (en) | 2018-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105167072A (zh) | 一种功能性枸杞酵素及其制品的生产方法 | |
CN101228951A (zh) | 生物复合多糖高效营养液的制作方法 | |
CN103820368A (zh) | 醋酸菌冻干菌粉的制备方法及用途 | |
CN108135951B (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于防止脱发或促进生发的组合物 | |
WO2016010182A1 (ko) | 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 간기능 개선용 조성물 | |
CN106999520A (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于抗氧化的组合物 | |
KR101712590B1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 피로회복 증진용 조성물 | |
CN108463123A (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于降血压的组合物 | |
CN106998777B (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于镇定神经的组合物 | |
CN107001487A (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于改善性功能的组合物 | |
WO2016010183A1 (ko) | 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 지질 관련 대사 개선용 조성물 | |
CN102648924A (zh) | 红缘拟层孔菌发酵产物的抗肿瘤和增强免疫活性 | |
CN107182201A (zh) | 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于预防或者治疗癌症的药学组合物 | |
CN110229131B (zh) | 角果木内生真菌来源的苯并吡喃酮衍生物及其制备方法与应用 | |
KR101737626B1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 과잉 면역 억제용 조성물 | |
CN109223735A (zh) | 从杂色曲霉次级代谢物中分离出的活性化合物的用途 | |
KR100624101B1 (ko) | 노루궁뎅이 버섯의 추출물을 포함하는 알코올 분해 촉진용조성물 | |
US9717769B2 (en) | Method for protecting kidney function | |
RU2601123C1 (ru) | ШТАММ Candida albicans var. stellatoidea ДЛЯ ПОЛУЧЕНИЯ ДИАГНОСТИЧЕСКОГО АЛЛЕРГЕНА | |
TWI545191B (zh) | 靈芝培養基及其應用 | |
CN108315158A (zh) | 一种桃花白酒及其制备方法 | |
CN101559119A (zh) | 一种食用真菌的组合物和应用 | |
CN106176827A (zh) | 降低癌细胞抗药性的樟芝菌丝体萃取物及其活性物质和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |